Hood River Capital Management LLC Increases Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Hood River Capital Management LLC increased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 6.7% during the second quarter, Holdings Channel.com reports. The institutional investor owned 1,572,929 shares of the biopharmaceutical company’s stock after buying an additional 98,892 shares during the period. Hood River Capital Management LLC’s holdings in TG Therapeutics were worth $27,982,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TGTX. Norges Bank purchased a new stake in TG Therapeutics during the fourth quarter worth about $18,362,000. Assenagon Asset Management S.A. purchased a new stake in shares of TG Therapeutics during the 2nd quarter worth approximately $8,698,000. Eventide Asset Management LLC purchased a new stake in shares of TG Therapeutics during the 4th quarter worth approximately $7,506,000. Opaleye Management Inc. raised its holdings in shares of TG Therapeutics by 17.2% in the 4th quarter. Opaleye Management Inc. now owns 2,215,000 shares of the biopharmaceutical company’s stock worth $37,832,000 after purchasing an additional 325,000 shares during the period. Finally, UBS Group AG lifted its stake in TG Therapeutics by 67.2% in the fourth quarter. UBS Group AG now owns 564,836 shares of the biopharmaceutical company’s stock valued at $9,647,000 after purchasing an additional 226,971 shares during the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $24.65 on Monday. TG Therapeutics, Inc. has a twelve month low of $6.46 and a twelve month high of $26.41. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58. The stock has a market cap of $3.81 billion, a P/E ratio of 107.17 and a beta of 2.21. The business’s 50-day moving average price is $22.08 and its two-hundred day moving average price is $18.35.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The business had revenue of $73.47 million for the quarter, compared to the consensus estimate of $65.92 million. During the same period last year, the firm posted ($0.34) earnings per share. TG Therapeutics’s quarterly revenue was up 357.0% on a year-over-year basis. As a group, equities analysts predict that TG Therapeutics, Inc. will post 0.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on TGTX shares. The Goldman Sachs Group raised their target price on TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $49.00 price target on shares of TG Therapeutics in a research note on Wednesday, September 18th. Finally, B. Riley boosted their price objective on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.83.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.